Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells $243,668.03 in Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Catriona Yale sold 8,851 shares of the stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $27.53, for a total transaction of $243,668.03. Following the completion of the transaction, the insider now owns 75,931 shares in the company, valued at $2,090,380.43. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Catriona Yale also recently made the following trade(s):

• On Monday, August 26th, Catriona Yale sold 5,200 shares of Akero Therapeutics stock. The shares were sold at an average price of $27.51, for a total transaction of $143,052.00.
• On Tuesday, June 11th, Catriona Yale sold 2,825 shares of Akero Therapeutics stock. The stock was sold at an average price of $22.64, for a total transaction of $63,958.00.

Akero Therapeutics Stock Up 1.2 %

Akero Therapeutics stock opened at $27.20 on Friday. The stock has a 50 day moving average of $25.21 and a two-hundred day moving average of $23.69. Akero Therapeutics, Inc. has a twelve month low of $11.25 and a twelve month high of $53.77. The stock has a market capitalization of $1.88 billion, a price-to-earnings ratio of -8.36 and a beta of -0.28. The company has a current ratio of 30.12, a quick ratio of 30.12 and a debt-to-equity ratio of 0.04.

Akero Therapeutics (NASDAQ:AKRO) last issued its quarterly earnings results on Friday, August 9th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.09. As a group, research analysts expect that Akero Therapeutics, Inc. will post -3.82 earnings per share for the current year.

Institutional Trading of Akero Therapeutics

Several hedge funds have recently made changes to their positions in AKRO. Strs Ohio raised its holdings in Akero Therapeutics by 100.0% during the fourth quarter. Strs Ohio now owns 2,000 shares of the company’s stock worth $46,000 after purchasing an additional 1,000 shares in the last quarter. abrdn plc purchased a new position in shares of Akero Therapeutics during the 4th quarter worth approximately $1,671,000. New York State Common Retirement Fund raised its stake in shares of Akero Therapeutics by 3.6% during the 4th quarter. New York State Common Retirement Fund now owns 34,545 shares of the company’s stock worth $807,000 after buying an additional 1,214 shares in the last quarter. Headlands Technologies LLC acquired a new stake in shares of Akero Therapeutics in the 4th quarter valued at approximately $28,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Akero Therapeutics by 1.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 425,545 shares of the company’s stock valued at $9,936,000 after buying an additional 6,115 shares in the last quarter.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Akero Therapeutics in a report on Thursday, June 20th. HC Wainwright restated a “buy” rating and set a $50.00 price target on shares of Akero Therapeutics in a research note on Monday, August 12th. Evercore ISI reduced their price objective on Akero Therapeutics from $50.00 to $38.00 and set an “outperform” rating for the company in a research note on Wednesday, May 15th. Canaccord Genuity Group decreased their price objective on Akero Therapeutics from $59.00 to $56.00 and set a “buy” rating for the company in a report on Monday, May 13th. Finally, Wolfe Research assumed coverage on shares of Akero Therapeutics in a report on Tuesday, June 11th. They issued an “outperform” rating on the stock. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $41.13.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.